Introduction
Methods
Literature search
Eligibility criteria
Selection of eligible studies
Data extraction
Risk of bias assessment
Statistical analysis
Results
Study and patient characteristics
BMI | < 25 kg/m2 | 25–29.9 kg/m2 | 30–34.9 kg/m2 | ≥ 35 kg/m2 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
study | DELIVER | DAPA-HF | EMPEROR-R | DELIVER | DAPA-HF | EMPEROR-R | DELIVER | DAPA-HF | EMPEROR-R | DELIVER | DAPA-HF | EMPEROR-R | |
n | SGLT2i | 709(50.8%) | 672(49.9%) | 599(49.2%) | 1025(49.4%) | 865(50.2%) | 664(49.4%) | 772(49%) | 512(50.5%) | 406(52.5%) | 623(51.4%) | 322(48.9%) | 194(49.4%) |
Placebo | 688(49.2%) | 676(50.1%) | 619(50.8%) | 1048(50.6%) | 857(49.8%) | 681(50.6%) | 802(51%) | 501(49.5%) | 368(47.5%) | 590(48.6%) | 337(51.1%) | 199(50.6% | |
Age | 73.4 ± 10 | 67 ± 12 | 67.8 ± 11.4 | 72.4 ± 9.5 | 67 ± 10 | 67.6 ± 10.6 | 71.4 ± 9 | 66 ± 10 | 65.4 ± 10.5 | 68.8 ± 9.1 | 63 ± 11 | 64 ± 11.7 | |
Female | 603(43.2%) | 334(24.8%) | 302(24.8%) | 828(39.9%) | 346(20.1%) | 281(20.9%) | 676(42.9%) | 227(22.4%) | 182(23.5%) | 635(52.3%) | 202(30.7%) | 128(32.6%) | |
Asian | 669(49.7%) | 656(48.7%) | 442(36.3%) | 453(21.9%) | 349(20.3%) | 173(12.9%) | 119(7.6%) | 87(8.6%) | 45(5.8%) | 32(2.6%) | 24(6.7%) | 12(3.1%) | |
Black | 25(1.8%) | 47(3.5%) | 80(6.6%) | 47(2.7%) | 69(4%) | 96(7.1%) | 32(2%) | 58(5.7%) | 48(6.2%) | 55(4.5%) | 52(7.9%) | 33(8.3%) | |
White | 601(43%) | 621(46.1%) | 638(52.4%) | 1427(68.8%) | 1283(74.5%) | 1018(75.7%) | 1333(84.7%) | 854(84.3%) | 643(83.1%) | 1073(88.5%) | 573(86.9%) | 330(84%) | |
NYHA III/IV | 287(20.5%) | 374(27.7%) | 271(22.3%) | 439(21.2%) | 528(30.7%) | 297(22.1%) | 414(26.3%) | 362(35.7%) | 221(28.6%) | 408(33.6%) | 263(39.9%) | 141(35.9%) | |
Diabetes | 434(31.1%) | 431(32%) | 503(41.3%) | 885(42.7%) | 665(38.6%) | 661(49.1%) | 782(49.7%) | 500(49.4%) | 452(58.4%) | 703(58%) | 387(58.7%) | 240(61.1%) | |
Hypertension | 1113(79.7%) | 835(61.9%) | NA | 1812(87.4%) | 1277(74.2%) | NA | 1474(93.6%) | 836(82.5%) | NA | 1148(94.6%) | 572(86.8%) | NA | |
Atrial fibrillation | 751(53.8%) | 435(32.3%) | 403(33.1%) | 1060 | 672(39%) | 488(36.3%) | 929(59%) | 406(40.1%) | 308(39.8%) | 486(40.1%) | 305(46.3%) | 170(43.3%) | |
LVEF | 53.2 ± 10.1 | 30 ± 7 | 27.4 ± 6.2 | 53 ± 10 | 31 ± 7 | 27.5 ± 6 | 54 ± 10 | 32 ± 7 | 27.6 ± 5.8 | 54.3 ± 9.4 | 31 ± 7 | 27.3 ± 6.2 | |
Prior HHF | 611(43.7%) | 656(48.7%) | 387(31.8%) | 817(39.4%) | 827(48%) | 394(29.3%) | 625(39.7%) | 462(45.6%) | 234(30.2%) | 482(39.7%) | 305(46.3%) | 136(34.6%) | |
Beta-blockers | 1074(76.9%) | 1254(93%) | 1128(92.6%) | 1694(81.7%) | 1663(96.6%) | 1283(95.4%) | 1353(86%) | 987(97.4%) | 744(96.1%) | 1051(86.6%) | 652(98.9%) | 378(96.2%) | |
ACEs or ARBs | 971(70%) | 1227(91%) | 809(66.4%) | 1594(76.9%) | 1638(95.1%) | 1225(91.1%) | 1289(81.9%) | 973(96.1%) | 719(92.9%) | 973(80.2%) | 636(96.5%) | 361(91.9%) | |
MRAs | 642(46%) | 961(71.3%) | 851(69.9%) | 869(41.9%) | 1209(70.2%) | 944(70.2%) | 679(43.1%) | 735(72.6%) | 561(72.5%) | 475(39.2%) | 465(70.6%) | 305(77.6%) | |
ICD | NA | 261(19.4%) | 285(23.4%) | NA | 467(27.1%) | 453(33.7%) | NA | 302(29.8%) | 288(37.2%) | NA | 210(31.9%) | 144(36.6%) |